EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis

Jiao Qiao, Mei Feng, Wenyuan Zhou, Yuan Tan, Shuo Yang, Qi Liu, Qingchen Wang, Weimin Feng, Yisheng Pan, Liyan Cui iD

Gastric Cancer · 2024

DOI: 10.1007/s10120-024-01508-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2024. Verfasst von Jiao Qiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Technology, Peking University Health Science Center, Beijing, 100191, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Clinical Key Specialty Excellence Program, P. R. China, Hospital-Enterprise Joint Funding Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) is a heterogeneous GC subtype characterized by the overexpression of HER2. To date, few specific targeted therapies have demonstrated durable efficacy in HER2-positive GC patients, with resistance to trastuzumab typically emerging within 1 year. However, the mechanisms of resistance to trastuzumab remain incompletely understood, presenting a significant challenge to clinical practice.

Methods

In this study, we integrated genetic screening and bulk transcriptome and epigenomic profiling to define the mechanisms mediating adaptive resistance to HER2 inhibitors and identify potential effective therapeutic strategies for treating HER2-positive GCs.

Results

We revealed a potential association between adaptive resistance to trastuzumab in HER2-positive GC and the expression of YES-associated protein (YAP). Notably, our investigation revealed that long-term administration of trastuzumab triggers extensive chromatin remodeling and initiates YAP gene transcription in HER2-positive cells characterized by the initial inhibition and subsequent reactivation. Furthermore, treatment of HER2-positive GC cells and cell line-derived xenografts (CDX) models with YAP inhibitors in combination with trastuzumab was found to induce synergistic effects through the AKT/mTOR and ERK/mTOR pathways.

Conclusion

These findings underscore the pivotal role of reactivated YAP and mTOR signaling pathways in the development of adaptive resistance to trastuzumab and may serve as a promising joint target to overcome resistance to trastuzumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesDrug Resistance, NeoplasmTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktTranscription FactorsHumansAnimalsMiceAntineoplastic Agents, ImmunologicalYAP-Signaling ProteinsXenograft Model Antitumor AssaysSignal TransductionAdaptor Proteins, Signal TransducingFemaleCell Line, TumorMice, NudeCell Proliferation

Stichwörter der Autor:innen

Adaptive resistanceDrug combinationHER2-positive gastric cancerTrastuzumabYAP

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktTranscription FactorsAntineoplastic Agents, ImmunologicalYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingERBB2 protein, humanMTOR protein, human

Autor:innen und Institutionen

  • Institute of Medical Technology, Peking University Health Science Center, Beijing, 100191, China.
  • Department of Laboratory Medicine, Peking University Third Hospital, Beijing, 100191, China.
  • Core Unit of National Clinical Research Center for Laboratory Medicine, Peking University Third Hospital, Beijing, 100191, China.
  • Translational Cancer Research Center, Peking University First Hospital, Beijing, 100034, China.
  • Division of General Surgery, Peking University First Hospital, Peking University, No. 8 Xi Shiku Street, Beijing, 100034, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department…

ORCID-Profile: Liyan Cui

Förderung

  • Beijing Clinical Key Specialty Excellence Program, P. R. China
  • Hospital-Enterprise Joint Funding Project

Zitieren

APA

Qiao, J., Feng, M., Zhou, W., Tan, Y., Yang, S., Liu, Q., Wang, Q., Feng, W., Pan, Y., & Cui, L. (2024). YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis. Gastric Cancer. https://doi.org/10.1007/s10120-024-01508-3

Vancouver

Qiao J, Feng M, Zhou W, Tan Y, Yang S, Liu Q, et al. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis. Gastric Cancer. 2024. doi:10.1007/s10120-024-01508-3

BibTeX
@article{Qiao2024,
  author = {Qiao, Jiao and Feng, Mei and Zhou, Wenyuan and Tan, Yuan and Yang, Shuo and Liu, Qi and Wang, Qingchen and Feng, Weimin and Pan, Yisheng and Cui, Liyan},
  title = {YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis},
  journal = {Gastric Cancer},
  year = {2024},
  doi = {10.1007/s10120-024-01508-3}
}
Kostenlos starten →